Advertisement

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Welcome and Introduction to Vi3C

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Peter Clark, MA, MD, FRCP: A Payer Perspective

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Apr
22
Today In Oncology
Claim Denials for Medicare Cancer-Related NGS Testing Show Uncertainty of Coverage
Radiotherapy Dosing for Head and Neck Squamous Cell Carcinoma
Extended Follow-up of Belzutifan Treatment for von Hippel-Lindau Disease-Associated RCC
MRD and Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC
Role of Pathologists in Improving Access to Safer More Effective Allogeneic Cell Therapies
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo